Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Atrimustine is a conjugate of chlorambucil and β-estradiol benzoate. It has the antitumor activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 916.00 | |
50 mg | 6-8 weeks | $ 1,190.00 | |
100 mg | 6-8 weeks | $ 1,860.00 |
Description | Atrimustine is a conjugate of chlorambucil and β-estradiol benzoate. It has the antitumor activity. |
In vitro | Atrimustine (Bestrabucil), a conjugate combining chlorambucil with β-estradiol benzoate, exhibits a high affinity for tumor cells, thereby boosting the antitumor efficacy of chlorambucil[1]. This compound demonstrates concentration-dependent inhibition of growth factor production in Shionogi carcinoma 115 (SC-115) cells, an androgen-responsive cancer cell line, across a range of 100 nM to 10 μM. This inhibition is evidenced through a 3H-thymidine uptake assay[2], highlighting Atrimustine's potential in hindering cancer cell proliferation. |
Synonyms | KM2210, Bestrabucil |
Molecular Weight | 720.72 |
Formula | C41H47Cl2NO6 |
CAS No. | 75219-46-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Atrimustine 75219-46-4 Others KM 2210 KM2210 KM-2210 Bestrabucil inhibitor inhibit